Pancreatic Cancer
1,937
308
411
810
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
292 trials with published results (15%)
Research Maturity
810 completed trials (42% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.2%
236 terminated out of 1937 trials
77.4%
-9.1% vs benchmark
6%
125 trials in Phase 3/4
36%
292 of 810 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 810 completed trials
Clinical Trials (1937)
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic Pancreatitis
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
Early Screening of Pancreatic Lesions : Development of New Imaging Tools
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Study of DM002 in Patients With Advanced Solid Tumors
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
A Study of PHN-012 in Patients With Advanced Solid Tumors